Free Newsletter
China suspends vax doses following minor's death
China's Sinovac Biotech says that health officials in Beijing suspended the use of 83 doses of the inactivated hepatitis A vaccine Healive after a minor died two days after being vaccinated. Sinovac noted that out of the 19,850 doses distributed from the same lot of vaccines, no other adverse events had been recorded.
On November 29, regulators inspected Sinovac's manufacturing facility and reviewed its inspections and sales process without finding any irregularities, according to the company. Sinovac says it will continue to cooperate with the authorities and plans a follow-up report.
- check out the Sinovac release
- read RTTNews coverage
Related Article:
Sinovac to mass produce bird flu vaccine (2006)
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
